US-based Abide Therapeutics has started dosing patients in a Phase Ib clinical trial of ABX-1431 for the treatment of tourette syndrome (TS).

Abide has also partnered with the Tourette Association of America (TAA) to understand the unmet needs in the Tourette community.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ABX-1431 is an investigational, orally available, small-molecule monoacylglycerol lipase (MGLL) inhibitor.

The cross-over Phase 1b trial will evaluate the ability of ABX-1431 to modulate the endocannabinoid neurotransmitter system activity.

The trial aims to determine the effect of a highly specific endocannabinoid modulator when assessed under controlled conditions compared to established benefits of exocannabinoids.

"Following the completion of dosing in the Phase Ia trial, ABX-1431 was found to be well tolerated without any serious adverse events."

Abide Therapeutics president and chief executive officer Alan Ezekowitz said: "We are excited to begin this trial in adults with Tourette Syndrome, and we hope to subsequently extend our studies to children, since Tourette Syndrome is largely considered to be a disease of childhood.

"As we continue to explore the potential utility of ABX-1431 in Tourette Syndrome, we are grateful for the opportunity to partner with the TAA to further understand the challenges faced by those affected by the condition."

Following the completion of dosing in the Phase Ia trial, ABX-1431 was found to be well tolerated without any serious adverse events.

According to the preliminary data from a PET occupancy study, ABX-1431 showed dose-dependent brain penetrance via Abide's MGLL-specific PET ligand known as [18F]ABX-1488.

Additionally, the firm is planning to begin dosing patients in a fMRI trial investigating ABX-1431-related neural activity patterns in the brain.